Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Meet Medicilon at CBA 27th Annual Conference!

2022-12-06
|
Page View:

 

Meet Medicilon at CBA 27th Annual Conference! It kicks off on December 17, 2022 in Maryland. As we all know, CBA is most famous for its annual meeting. Medicilon is honored to participate this year. The theme is Empowering Healthcare with Cutting-Edge Biopharma Technologies and Leading Global Partnerships. Dr. Guo Zhenrong, executive vice president of our pharmaceutical research sector Join the meeting with the Medicilon US team and look forward to communicating with you face to face!

 

About CBA 27th Annual Conference

The Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the US. Founded in 1995, CBA is an independent, non-political, not-for-profit professional organization led by its elected board of directors, the board of advisors, and executive committees. The most influential event of CBA is its annual conference that attracts hundreds to thousands of attendees each year. Many internationally renowned scientists, business leaders, and the high-ranking US and Chinese government officials have attended and spoken at CBA’s annual conferences. To promote collaborations between the Chinese and American biopharmaceutical industries, and to further strengthen CBA‘s influence in the global biopharmaceutical industry, CBA has strategically stepped up its activities in connecting both industries.

 

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

 

Medicilon Drug Discovery Services

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

 

Innovative Drug R&D Services

Antibody-Drug Conjugate (ADC)

 

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

 

Proteolysis Targeting Chimera (PROTAC) 

 

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

 

mRNA Vaccine Bioanalysis Platform

 

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines.  We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.

 

AI R&D Innovation

 

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

 

 

 


Share:
Return
Relevant newsRelevant news